A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate

Summary

This study will assess the safety, tolerability and blood concentrations of lasmiditan and topiramate together compared to lasmiditan and topiramate separately. Information about any side effects that may occur will be collected. Participants will be admitted to the Clinical Research Unit (CRU) one day prior to the start of the study and will remain through Day 14. This study is expected to last approximately 25 days, not including screening. Screening is required within 28 days prior to the start of the study.

Timeline

Start

2017-10-16

Primary completion

2017-12-02

Completion

2017-12-02

Drugs

Indications

No indication recorded.